Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

<p>Expression of chr1q genes in BRAFV600E with chr1q gain and copy number quiet tumors in the TCGA RNAseq dataset.</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Laura Boucai (15054310) (author)
Eará dahkkit:	Mahesh Saqcena (15054313) (author), Fengshen Kuo (14947443) (author), Ravinder K. Grewal (15054316) (author), Nicholas Socci (15054319) (author), Jeffrey A. Knauf (15008595) (author), Gnana P. Krishnamoorthy (15054322) (author), Mabel Ryder (15054325) (author), Alan L. Ho (15054328) (author), Ronald A. Ghossein (15054331) (author), Luc G.T. Morris (14956461) (author), Venkatraman Seshan (15054334) (author), James A. Fagin (15054337) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Endocrine-Related Cancers Precision Medicine
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Dahkki: Laura Boucai (15054310)
Almmustuhtton: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Dahkki: Athanasios Bikas (16006076)
Almmustuhtton: (2025)

Supplementary Tables S1-S11 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Dahkki: Yoann Pradat (15352227)
Almmustuhtton: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Dahkki: Naveen S. Vasudev (15057037)
Almmustuhtton: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Dahkki: Naveen S. Vasudev (15057037)
Almmustuhtton: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Dahkki: Iris van 't Erve (15054503)
Almmustuhtton: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Dahkki: Katleen Janssens (15053356)
Almmustuhtton: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
Dahkki: Anna Eriksson (15352461)
Almmustuhtton: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
Dahkki: Anna Eriksson (15352461)
Almmustuhtton: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Dahkki: Raphaël Leman (17314506)
Almmustuhtton: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Dahkki: Raphaël Leman (17314506)
Almmustuhtton: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Dahkki: Raphaël Leman (17314506)
Almmustuhtton: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Dahkki: Raphaël Leman (17314506)
Almmustuhtton: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Dahkki: Raphaël Leman (17314506)
Almmustuhtton: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Dahkki: Raphaël Leman (17314506)
Almmustuhtton: (2025)

Supplementary Table 1 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 10 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 11 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 12 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 13 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 14 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 2 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 3 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 4 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 5 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 6 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 7 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 8 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Supplementary Table 9 from The Effect of Circulating Proteins and Their Role in Mediating Adiposity’s Effect on Endometrial Cancer Risk: Mendelian Randomization and Colocalization Analyses
Dahkki: Sabrina E. Wang (22165247)
Almmustuhtton: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Dahkki: Nigel Bundred (15046233)
Almmustuhtton: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Dahkki: Nigel Bundred (15046233)
Almmustuhtton: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Dahkki: Nigel Bundred (15046233)
Almmustuhtton: (2025)